Er +/Her2 -Ve Breast Cancer Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Er +/Her2 -Ve Breast Cancer pipeline constitutes 20+ key companies continuously working towards developing 25+ Er +/Her2 -Ve Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Er +/Her2 -Ve Breast Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Er +/Her2 -Ve Breast Cancer Market.

The Er +/Her2 -Ve Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Er +/Her2 -Ve Breast Cancer Pipeline Report: https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Er +/Her2 -Ve Breast Cancer treatment therapies with a considerable amount of success over the years.
• Er +/Her2 -Ve Breast Cancer companies working in the treatment market are EnhancedBio Inc., Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Genentech, and others, are developing therapies for the Er +/Her2 -Ve Breast Cancer treatment
• Emerging Er +/Her2 -Ve Breast Cancer therapies in the different phases of clinical trials are- ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others are expected to have a significant impact on the Er +/Her2 -Ve Breast Cancer market in the coming years.
• In January 2025, Endocrine therapy combined with CDK4/6 inhibitors is the standard approach for treating estrogen receptor-positive, HER2-negative metastatic breast cancer (ER+/HER2- MBC), though resistance commonly emerges over time. Previous studies showed that low doses of palbociclib can trigger autophagy, which helps cancer cells bypass the initial G1 cell cycle arrest, while higher doses lead to unintended senescence. However, combining palbociclib with the autophagy inhibitor hydroxychloroquine (HCQ) promoted desired, on-target senescence even at lower palbociclib doses. To evaluate this combination, a Phase I clinical trial (NCT03774472, registered on ClinicalTrials.gov on August 20, 2018) was conducted using a 3 + 3 dose-escalation design. The trial tested HCQ at 400, 600, and 800 mg/day alongside continuous palbociclib (75 mg/day) and letrozole.
• In December 2024, Incyclix Bio, LLC, a company focused on next-generation cell cycle regulation, is developing INX-315-a novel, selective, and potent CDK2 inhibitor-for the treatment of advanced and therapy-resistant cancers. The company recently shared interim results from the dose-escalation phase of its ongoing Phase 1/2 clinical trial, INX-315-01. The trial is evaluating INX-315 in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer that has developed resistance to CDK4/6 inhibitors, as well as those with CCNE1-amplified solid tumors. These findings were presented at the 2024 San Antonio Breast Cancer Symposium (SABCS).
• In December 2024, Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), demonstrated improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer who had previously received endocrine therapy. In the Phase III EMBER-3 clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), imlunestrant showed efficacy as a monotherapy in patients with ESR1 mutations and also in combination with abemaciclib (Verzenio) across all patients, regardless of ESR1 mutation status.

Er +/Her2 -Ve Breast Cancer Overview
ER-positive/HER2-negative (ER+/HER2-) breast cancer is a type of breast cancer where the tumor cells have receptors for estrogen (ER+) but do not have excess human epidermal growth factor receptor 2 (HER2-). This means the cancer grows in response to estrogen but does not rely on HER2 signals for growth. It is the most common subtype of breast cancer and is typically treated with endocrine (hormone) therapies, often combined with targeted treatments like CDK4/6 inhibitors.

Get a Free Sample PDF Report to know more about Er +/Her2 -Ve Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Er +/Her2 -Ve Breast Cancer Drugs Under Different Phases of Clinical Development Include:
• ER-PROTAC: EnhancedBio Inc.
• RLY-2608: Relay Therapeutics, Inc.
• PRT2527: Prelude Therapeutics
• EP0062: Ellipses Pharma
• BPI-1178: Beta Pharma
• CX-2009: CytomX Therapeutics
• Z-endoxifen: Atossa Therapeutics, Inc
• AZD9833: AstraZeneca
• GDC-9545: Roche
• Gedatolisib: Celcuity, Inc.
• BGB-290: BeiGene
• OP-1250: Olema Pharmaceuticals, Inc.
• AZD9833: AstraZeneca
• ADG106: Adagene Inc
• Dato-DXd: Daiichi Sankyo, Inc.
• HRS8807: Shanghai Hengrui Pharmaceutical Co.
• Ipatasertib: Genentech

Er +/Her2 -Ve Breast Cancer Route of Administration
Er +/Her2 -Ve Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Er +/Her2 -Ve Breast Cancer Molecule Type
Er +/Her2 -Ve Breast Cancer Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Er +/Her2 -Ve Breast Cancer Pipeline Therapeutics Assessment
• Er +/Her2 -Ve Breast Cancer Assessment by Product Type
• Er +/Her2 -Ve Breast Cancer By Stage and Product Type
• Er +/Her2 -Ve Breast Cancer Assessment by Route of Administration
• Er +/Her2 -Ve Breast Cancer By Stage and Route of Administration
• Er +/Her2 -Ve Breast Cancer Assessment by Molecule Type
• Er +/Her2 -Ve Breast Cancer by Stage and Molecule Type

DelveInsight's Er +/Her2 -Ve Breast Cancer Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Er +/Her2 -Ve Breast Cancer product details are provided in the report. Download the Er +/Her2 -Ve Breast Cancer pipeline report to learn more about the emerging Er +/Her2 -Ve Breast Cancer therapies
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Er +/Her2 -Ve Breast Cancer Therapeutics Market include:
Key companies developing therapies for Er +/Her2 -Ve Breast Cancer are - Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., Modra Pharmaceuticals, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., MedImmune LLC, QED Therapeutics, Inc., Tyme, Inc., PIQUR Therapeutics, Pfizer, andn others.

Er +/Her2 -Ve Breast Cancer Pipeline Analysis:
The Er +/Her2 -Ve Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Er +/Her2 -Ve Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Er +/Her2 -Ve Breast Cancer Treatment.
• Er +/Her2 -Ve Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Er +/Her2 -Ve Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Er +/Her2 -Ve Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Er +/Her2 -Ve Breast Cancer drugs and therapies
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Er +/Her2 -Ve Breast Cancer Pipeline Market Drivers
• HER2 protein is considered a relevant biomarker for treatment, growing prevalence of Breast Cancer are some of the important factors that are fueling the Er +/Her2 -Ve Breast Cancer Market.

Er +/Her2 -Ve Breast Cancer Pipeline Market Barriers
• However, poor understanding in the context of breast cancer subtype, lack of research in identification of factors involved in resistance and other factors are creating obstacles in the Er +/Her2 -Ve Breast Cancer Market growth.

Scope of Er +/Her2 -Ve Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key Er +/Her2 -Ve Breast Cancer Companies: EnhancedBio Inc., Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Genentech, and others
• Key Er +/Her2 -Ve Breast Cancer Therapies: ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others
• Er +/Her2 -Ve Breast Cancer Therapeutic Assessment: Er +/Her2 -Ve Breast Cancer current marketed and Er +/Her2 -Ve Breast Cancer emerging therapies
• Er +/Her2 -Ve Breast Cancer Market Dynamics: Er +/Her2 -Ve Breast Cancer market drivers and Er +/Her2 -Ve Breast Cancer market barriers

Request for Sample PDF Report for Er +/Her2 -Ve Breast Cancer Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/er-her2-ve-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Er +/Her2 -Ve Breast Cancer Report Introduction
2. Er +/Her2 -Ve Breast Cancer Executive Summary
3. Er +/Her2 -Ve Breast Cancer Overview
4. Er +/Her2 -Ve Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5. Er +/Her2 -Ve Breast Cancer Pipeline Therapeutics
6. Er +/Her2 -Ve Breast Cancer Late Stage Products (Phase II/III)
7. Er +/Her2 -Ve Breast Cancer Mid Stage Products (Phase II)
8. Er +/Her2 -Ve Breast Cancer Early Stage Products (Phase I)
9. Er +/Her2 -Ve Breast Cancer Preclinical Stage Products
10. Er +/Her2 -Ve Breast Cancer Therapeutics Assessment
11. Er +/Her2 -Ve Breast Cancer Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Er +/Her2 -Ve Breast Cancer Key Companies
14. Er +/Her2 -Ve Breast Cancer Key Products
15. Er +/Her2 -Ve Breast Cancer Unmet Needs
16 . Er +/Her2 -Ve Breast Cancer Market Drivers and Barriers
17. Er +/Her2 -Ve Breast Cancer Future Perspectives and Conclusion
18. Er +/Her2 -Ve Breast Cancer Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Cardiac Rhythm Management Devices Market: https://www.delveinsight.com/report-store/cardiac-rhythm-management-devices-market
• Tumor Ablation Market: https://www.delveinsight.com/report-store/tumor-ablation-market
• Fibromyalgia Market: https://www.delveinsight.com/report-store/fibromyalgia-market
• Vascular Access Devices Market: https://www.delveinsight.com/report-store/vascular-access-device-market
• India Healthcare Report: https://www.delveinsight.com/report-store/india-healthcare-outlook-report
• Implantable Cardioverter Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Monkeypox Market: https://www.delveinsight.com/report-store/monkeypox-market

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.